Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, U-Neuron Biomedical's Enterprise Value is NT$701.39 Mil.
U-Neuron Biomedical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-54.67 Mil. Therefore, U-Neuron Biomedical's EV-to-EBIT ratio for today is -12.83.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, U-Neuron Biomedical's Enterprise Value is NT$701.39 Mil.
U-Neuron Biomedical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-40.15 Mil. Therefore, U-Neuron Biomedical's EV-to-EBITDA ratio for today is -17.47.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, U-Neuron Biomedical's Enterprise Value is NT$701.39 Mil.
U-Neuron Biomedical's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$82.66 Mil. Therefore, U-Neuron Biomedical's EV-to-Revenue ratio for today is 8.48.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
U-Neuron Biomedical (ROCO:6973) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-54.67 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-40.15 Mil.
U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$82.66 Mil.
U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-41.36 Mil.
U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-85.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical Enterprise Value Related Terms
U-Neuron Biomedical Enterprise Value Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
U-Neuron Biomedical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$701.39 Mil mean?
U-Neuron Biomedical (ROCO:6973) has a Enterprise Value of NT$701.39 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on U-Neuron Biomedical and its competitors.
Is U-Neuron Biomedical's Enterprise Value too high?
U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil. Overall, U-Neuron Biomedical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Enterprise Value compare to VRTX and REGN?
U-Neuron Biomedical's Enterprise Value of NT$701.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on U-Neuron Biomedical and its competitors. U-Neuron Biomedical's current Enterprise Value is NT$701.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
U-Neuron Biomedical (ROCO:6973) has a current Enterprise Value of NT$701.39 Mil. The current Enterprise Value is NT$701.39 Mil. U-Neuron Biomedical's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Enterprise Value is NT$701.39 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
12GF Score
Get the complete analysis for ROCO:6973
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
